SERENA 2 | D8530C00002
NCT04214288
JCP079
A Comparative Study of AZD9833 Versus Fulvestrant in Women With Advanced ER-Positive HER2-Negative Breast Cancer (SERENA-2)
Status:
Recruiting
II
Phase
2nd
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
ER+, HER2-
Investigational
Product
AZD9833
Selective degrader of the estrogen receptor (SERD) (p.o.)
Treatment Arms
o Experimental: AZD9833 Dose A
o Experimental: AZD9833 Dose B
o Experimental: AZD9833 Dose C
o Active Comparator: Fulvestrant 500 mg